REPL
Replimune Group, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -21.1% ·
share flow -0.6% ·
net new positions -20.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 75 | +2 | 45.55M | $503.98M | +13 | −11 |
| Q1 2026 | 75 | +4 | 41.32M | $315.89M | +10 | −6 |
| Q4 2025 | 71 | +3 | 45.45M | $441.76M | +3 | n/a |
| Q3 2025 | 15 | -4 | 32.26M | $135.16M | n/a | −4 |
| Q2 2025 | 16 | 0 | 29.86M | $277.39M | n/a | n/a |
| Q1 2025 | 13 | 0 | 20.78M | $202.64M | n/a | n/a |
| Q4 2024 | 13 | +1 | 19.63M | $237.78M | +2 | −1 |
| Q3 2024 | 11 | +1 | 14.48M | $158.71M | +1 | n/a |
| Q2 2024 | 10 | n/a | 16.01M | $144.07M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 8.31M | -23.2% | $34.80M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 2 | BlackRock ✦ (passive) | 5.78M | +0.8% | $24.20M | 0.0% | ▲ Add | 2 | SEC ↗ ×12 |
| 3 | Point72 Asset Management ✦ | 3.63M | +409.4% | $15.21M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | The Vanguard Group ✦ (passive) | 3.48M | +0.3% | $14.58M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 5 | State Street Global Advisors ✦ (passive) | 2.92M | +19.2% | $12.25M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 1.70M | +4.4% | $7.11M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Millennium Management ✦ | 1.59M | +100.2% | $6.66M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 8 | Morgan Stanley ✦ | 1.38M | n/a | $5.76M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 9 | Fidelity (FMR) ✦ | 1.36M | +247.5% | $5.70M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Goldman Sachs Group ✦ | 1.13M | n/a | $4.75M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | D. E. Shaw & Co. ✦ | 403.50K | -20.4% | $1.69M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 12 | Wellington Management ✦ | 227.02K | -76.0% | $951,197 | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 13 | Two Sigma Investments ✦ | 157.50K | +602.5% | $659,921 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 120.23K | -56.7% | $503,773 | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 15 | JPMorgan Chase ✦ | 76.03K | n/a | $318,574 | 0.0% | n/c | 1 | SEC ↗ ×6 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $17.34M | was 0.0% |
| Renaissance Technologies | $1.42M | was 0.0% |
| Fisher Asset Management | $761,306 | was 0.0% |
| AQR Capital Management | $113,450 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 178 holders, 80.31M shares, $547.04M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 9.26K sh · $132,176
Officer · 11.45K sh · $148,481
Officer, Director · 39.34K sh · $510,253
Officer · 7.63K sh · $98,987
Officer · 11.45K sh · $148,468
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
11.8% of class · View original SEC filing ↗